Characteristics of the 39 patients at study entry
| Patient characteristics . | . |
|---|---|
| Mean age, y (range) | 40 (22-65) |
| Sex (M/F) | 37/2 |
| Hemophilia A (%) | 30 (77) |
| Hemophilia B (%) | 7 (18) |
| Other inherited bleeding disorders (%) | 2 (5) |
| Disease duration, y (range) | 24 (14-40) |
| Mean ALT, IU/mL (range) | 135 (46-441) |
| Median HCV-RNA, MEq/mL (range) | 4.3 (< 0.2-43.0) |
| HCV genotype (%) | |
| 1a | 21 (54) |
| 1b | 8 (20) |
| 2b | 2 (5) |
| 3a | 7 (18) |
| 4 | 1 (3) |
| Outcome of previous IFN monotherapy (%) | |
| Nonresponse | 24 (62) |
| Transient response | 15 (38) |
| Patient characteristics . | . |
|---|---|
| Mean age, y (range) | 40 (22-65) |
| Sex (M/F) | 37/2 |
| Hemophilia A (%) | 30 (77) |
| Hemophilia B (%) | 7 (18) |
| Other inherited bleeding disorders (%) | 2 (5) |
| Disease duration, y (range) | 24 (14-40) |
| Mean ALT, IU/mL (range) | 135 (46-441) |
| Median HCV-RNA, MEq/mL (range) | 4.3 (< 0.2-43.0) |
| HCV genotype (%) | |
| 1a | 21 (54) |
| 1b | 8 (20) |
| 2b | 2 (5) |
| 3a | 7 (18) |
| 4 | 1 (3) |
| Outcome of previous IFN monotherapy (%) | |
| Nonresponse | 24 (62) |
| Transient response | 15 (38) |